<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04221165</url>
  </required_header>
  <id_info>
    <org_study_id>OPTIMAL HN</org_study_id>
    <nct_id>NCT04221165</nct_id>
  </id_info>
  <brief_title>Opioid Therapy vs Multimodal Analgesia in Head and Neck Cancer</brief_title>
  <official_title>Opioid Therapy vs Multimodal Analgesia in Head and Neck Cancer: A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ontario Institute for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the daily pain level scores for patients taking
      opioids alone for pain relief, compared with those treated by multimodal analgesia with three
      medications: pregabalin, naproxen, and acetaminophen, with the ability to switch over to
      opioid medications if needed. In addition to pain level scores, this study will compare
      opioid use (length of time and doses taken), quality of life, admissions to hospital, feeding
      tube requirements, weight loss, and treatment interruptions between these two analgesic
      regimens.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A significant proportion of patients undergoing radiotherapy alone or chemotherapy and
      radiotherapy together for their head and neck cancer experience mucositis, which is severe
      pain in the mouth and throat caused by radiation treatment. Patients often enter a cycle of
      pain, difficulty swallowing, malnourishment, and reduced quality of life. This may translate
      into decreased oral intake requiring a feeding tube, and radiation or chemotherapy treatment
      breaks, which reduce the chance of tumour control and cure.

      Currently, opioid therapy is the cornerstone of head and neck cancer pain management.
      Although effective for pain relief, opioids can have side effects.

      As an alternative to opioid treatments, &quot;multimodal analgesia&quot; is a treatment using
      medications from different classes with different mechanisms of action. Examples of analgesic
      medications used for multimodal analgesia include medications similar to acetaminophen or
      ibuprofen, and others.

      The primary purpose of this study is to compare pain level scores of patients taking opioids
      versus patients taking multimodal analgesia.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average Pain Rating measured on the 11 Numeric Rating Scale</measure>
    <time_frame>Approximately 2 years and 3 months</time_frame>
    <description>Average pain rating during the last 5 days or radiation therapy, as reported by the patient on the 11-Numeric Rating Scale (11-NRS). On the 11-NRS, zero (0) is no pain, and ten (10) is the worst possible pain.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Average Weekly Opioid Use</measure>
    <time_frame>Approximately 2 years and 4 months</time_frame>
    <description>The average weekly total opioid dose in oral morphine equivalent dosing from randomization to 6 weeks after completion of radiation treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Opioid Requirement</measure>
    <time_frame>Approximately 2 years and 6 months</time_frame>
    <description>The time from the start of opioid treatment after randomization to the time of stopping opioid analgesia, in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Daily 11-Numeric Rating Scale for Pain</measure>
    <time_frame>Approximately 2 years and 4 months</time_frame>
    <description>Average pain rating from the time of randomization until 6 weeks after completion of radiation treatment, as reported by the patient on the 11-Numeric Rating Scale (11-NRS). On the 11-NRS, zero (0) is no pain, and ten (10) is the worst possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)</measure>
    <time_frame>Approximately 24 months, 27 months, and 30 months</time_frame>
    <description>Quality of life, as reported by the patient, will be assessed using the EORTC QLQ-C30 validated questionnaire. Responses regarding function and symptoms are on a scale of 1 (not at all) to 4 (very much). Also included are questions about overall health and quality of life. Reponses are ona scale of 1 (very poor) to 7 (excellent).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - Head &amp; Neck 43 (EORTC QLQ-HN 43)</measure>
    <time_frame>Approximately 24 months, 27 months, and 30 months</time_frame>
    <description>Quality of life, as reported by the patient, will be assessed using the EORTC QLQ-HN 43 validated questionnaire. Responses regarding symptoms or problems are on a scale of 1 (not at all) to 4 (very much). This questionnaire is specifically for patients with head and neck cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average Weekly Opioids Dispensed</measure>
    <time_frame>Approximately 2 years and 4 months</time_frame>
    <description>The average weekly total opioid dose dispensed by the pharmacy in oral morphine equivalent dosing from randomization to 6 weeks after completion of radiation treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Admissions</measure>
    <time_frame>Approximately 27 months and 30 months</time_frame>
    <description>Hospital admissions for febrile neutropenia, serious infection requiring intravenous antibiotics, gastrointestinal bleeding, myocardial infarction, stroke, and acute kidney injury.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Feeding Tube Insertion</measure>
    <time_frame>Approximately 2 years and 3 months</time_frame>
    <description>The time to feeding tube insertion (e.g. gastrostomy-tube or nasogastric-tube) after randomization, in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Loss</measure>
    <time_frame>Approximately 2 years and 3 months</time_frame>
    <description>Weight loss from randomization to the end of radiation treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of Common Terminology Criteria for Adverse Events Toxicities</measure>
    <time_frame>Approximately 2 years and 6 months</time_frame>
    <description>Rates of pre-specified Common Terminology Criteria for Adverse Events (CTCAE) toxicities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Interruptions</measure>
    <time_frame>Approximately 2 years and 6 months</time_frame>
    <description>Radiation of chemotherapy treatment interruptions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Approximately 2 years and 6 months</time_frame>
    <description>Death during or within 3 months after completion of radiation treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Radiation-Induced Mucositis</condition>
  <arm_group>
    <arm_group_label>Opioid Analgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Opioids will be prescribed as per institutional standards. Examples of opioids are morphine and hydromorphone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multimodal Analgesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pregabalin (25 mg to 150 mg, oral, twice daily), acetaminophen (1000 mg, oral, 3 times per day), naproxen 250 mg to 500 mg, oral, twice daily), and pantoprazole magnesium (40 mg, oral, daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opioids</intervention_name>
    <description>Opioids will be prescribed as per institutional standards.</description>
    <arm_group_label>Opioid Analgesia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PAiN - multimodal analgesia</intervention_name>
    <description>PAiN: Pregabalin, Acetaminophen, Naproxen, pantoprazole magnesium</description>
    <arm_group_label>Multimodal Analgesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Willing to provide consent

          -  Histologically confirmed mucosal head and neck malignancy

          -  Undergoing chemoradiotherapy or radiotherapy alone with a planned total radiation dose
             of 50 Gray (Gy) or greater

          -  Eastern Co-operative Oncology Group (ECOG) performance status 0-2

          -  Life expectancy &gt; 6 months

          -  Onset of 4/10 pain on the 11-Numeric Rating Scale that is localized to the mucosa of
             the mouth or throat, before or during radiation treatment, that is not caused by a
             current oral candidiasis infection.

          -  Ability to take pills, either by mouth or crushed via NasoGastric (NG) tube or
             Gastrostomy tube (G-tube)

          -  Ability to complete the study questionnaires and pain diary

        Exclusion Criteria:

          -  Skin and salivary gland malignancies

          -  High daily opioid use at time of enrollment (defined as 30 mg oral morphine equivalent
             dose or higher)

          -  Concurrent second active malignancy

          -  Pregnant or lactating women

          -  Psychological disorder requiring pharmacologic treatment

          -  Regular systemic steroid use

          -  Regular anticonvulsant or antidepressant use

          -  Renal Impairment (defined as creatinine clearance &lt; 60 mL/min)

          -  Liver Dysfunction (defined as total bilirubin &gt; 34.2 Âµmol/L)

          -  Documented true allergy to acetaminophen, NSAIDs, pregabalin or opioids

          -  History of upper gastrointestinal bleed

          -  Known bleeding disorder

          -  History of or current substance use disorder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Palma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lawson Health Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Palma, MD</last_name>
    <phone>519-685-8650</phone>
    <email>David.Palma@lhsc.on.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sondos Zayed, MD</last_name>
    <phone>519-685-8650</phone>
    <email>Sondos.Zayed@lhsc.on.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>London Regional Cancer Program of the Lawson Health Research Institute</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Elad S, Yarom N. The Search for an Effective Therapy and Pain Relief for Oral Mucositis. JAMA. 2019 Apr 16;321(15):1459-1461. doi: 10.1001/jama.2019.3269.</citation>
    <PMID>30990535</PMID>
  </reference>
  <reference>
    <citation>Lalla RV, Bowen J, Barasch A, Elting L, Epstein J, Keefe DM, McGuire DB, Migliorati C, Nicolatou-Galitis O, Peterson DE, Raber-Durlacher JE, Sonis ST, Elad S; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014 May 15;120(10):1453-61. doi: 10.1002/cncr.28592. Epub 2014 Feb 25. Review. Erratum in: Cancer. 2015 Apr 15;121(8):1339.</citation>
    <PMID>24615748</PMID>
  </reference>
  <reference>
    <citation>Mirabile A, Airoldi M, Ripamonti C, Bolner A, Murphy B, Russi E, Numico G, Licitra L, Bossi P. Pain management in head and neck cancer patients undergoing chemo-radiotherapy: Clinical practical recommendations. Crit Rev Oncol Hematol. 2016 Mar;99:100-6. doi: 10.1016/j.critrevonc.2015.11.010. Epub 2015 Dec 3. Review.</citation>
    <PMID>26712589</PMID>
  </reference>
  <reference>
    <citation>Alfieri S, Ripamonti CI, Marceglia S, Orlandi E, Iacovelli NA, Granata R, Cavallo A, Pozzi P, Boffi R, Bergamini C, Imbimbo M, Pala L, Resteghini C, Mirabile A, Locati LD, Licitra L, Bossi P. Temporal course and predictive factors of analgesic opioid requirement for chemoradiation-induced oral mucositis in oropharyngeal cancer. Head Neck. 2016 Apr;38 Suppl 1:E1521-7. doi: 10.1002/hed.24272. Epub 2016 Feb 5.</citation>
    <PMID>26849016</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>Analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Analgesics, Opioid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

